Vinblastine is a vinca alkaloid used to treat breast cancer, testicular cancer, neuroblastoma, Hodgkin's and non-Hodgkins lymphoma, mycosis fungoides, histiocytosis, and Kaposi's sarcoma. Antitumor alkaloid isolated from Vinca rosea.
- Mechanism
- Curator reviewed
The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
- Primary indication
- For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.Curator reviewed · 13 structured indications
- Formula / weight
- C46H58N4O9 · 810.9741 g/mol (avg)
- First approval
- Canada, 2013 · United States, 1996
- Also known as
- Vincaleukoblastine
- Code names
- NSC-47842
Resolves to
JXLYSJRDGCGARV-CFWMRBGOSA-NSMILES[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OCWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Vinblastine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account